BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/8/2026 9:12:21 AM | Browse: 3 | Download: 1
 |
Received |
|
2026-01-12 06:50 |
|
Peer-Review Started |
|
2026-01-12 06:52 |
|
First Decision by Editorial Office Director |
|
2026-01-19 09:04 |
|
Return for Revision |
|
2026-01-19 09:04 |
|
Revised |
|
2026-01-31 12:46 |
|
Publication Fee Transferred |
|
2026-02-03 09:45 |
|
Second Decision by Editor |
|
2026-03-16 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-16 11:48 |
|
Articles in Press |
|
2026-03-16 11:48 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-29 07:37 |
|
Publish the Manuscript Online |
|
2026-06-08 09:12 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
Given that Immunoglobulin-related digestive system disorders frequently mimic malignancies, leading to misdiagnosis, this review systematically maps the clinical spectrum from classical (pancreato-biliary) to rare (esophageal/mesenteric) manifestations. A key highlight is the paradigm shift from single-marker diagnosis to multidimensional biomarker assessment (e.g., plasma blasts, interferon-α-interleukin-33 axis). It focuses on the utility of these novel markers in monitoring disease activity and predicting fibrosis, providing evidence-based strategies for early recognition and personalized management. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Clinical features and biomarker research advances in immunoglobulin 4-related digestive system disorders
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yue Pan and Yu-Zhang Jiang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Open Research Project of the Huai'an ‘Tian Yixing’ Key Laboratory of Medical Laboratory Science |
HAP202004 |
|
| Corresponding Author |
Yu-Zhang Jiang, Professor, Department of Laboratory Medicine, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, No. 1 West Huanghe Road, Huai’an 223300, Jiangsu Province, China. jyz8848@163.com |
| Key Words |
Immunoglobulin 4-related disease; Biomarkers; Digestive system; Diagnosis; Pathogenesis |
| Core Tip |
Given that Immunoglobulin-related digestive system disorders frequently mimic malignancies, leading to misdiagnosis, this review systematically maps the clinical spectrum from classical (pancreato-biliary) to rare (esophageal/mesenteric) manifestations. A key highlight is the paradigm shift from single-marker diagnosis to multidimensional biomarker assessment (e.g., plasma blasts, interferon-α-interleukin-33 axis). It focuses on the utility of these novel markers in monitoring disease activity and predicting fibrosis, providing evidence-based strategies for early recognition and personalized management. |
| Publish Date |
2026-06-08 09:12 |
| Citation |
Pan Y, Jiang YZ. Clinical features and biomarker research advances in immunoglobulin 4-related digestive system disorders. World J Gastroenterol 2026; 32(23): 118782
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i23/118782.htm |
| DOI |
https://doi.org/10.3748/wjg.v32.i23.118782 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
